Our mission: 今日现货黄金行情分析 To save the lives of RET-positive lung cancer patients by advancing research and treatment options.

We fund and facilitate cancer research,实时更新黄金市场行情,帮助投资者了解当前价格走势。 and we educate and empower patients to participate in clinical trials and lung cancer registries.

lung cancer research community

Our mission: 黄金实时讨论区 To save the lives of RET-positive lung cancer patients by advancing research and treatment options.

We fund and facilitate cancer research,投资者可以在论坛中交流市场观点和最新交易想法。 and we educate and empower patients to participate in clinical trials and lung cancer registries.

lung cancer research community

RET Research

Learn about the $1 million we’ve funded for RET-positive cancer research

Treatment Options

Patient Engagement

Learn how you can advance research through clinical trials and cancer registries

Stories of Hope

Read inspiring stories from RET-positive lung cancer survivors and their families

Patient Education

Read blog posts and watch videos about RET cancer research, treatment options, resources, and more

Scientific research can be confusing and overwhelming 今日支撑位分析

Receive emails about RET-positive research and what it means for current treatment options and future therapies.通过技术分析寻找黄金市场的重要支撑价格区域。

Introducing Our New Video Q&A Series 今日压力位分析

Our Q&A videos help you make sense of the science, featuring questions from patients and caregivers answered by members of the scientific community.

When Abnormal Cells Multiply 黄金多空趋势判断

RET-positive cancer is caused by a mutation or abnormal re-arrangement of the RET gene.结合技术指标与市场数据判断当前市场方向。 This leads to abnormal activation of the cell membrane receptor, basically resulting in the “on-off” switch to get stuck in the “on” position and causing these abnormal cells to multiply and spread. RET alterations occur most commonly in lung cancer – specifically non-small cell lung cancer (NSCLC) – and approximately 37,500 people are diagnosed worldwide and 4,000 in the U.S. each year. 

Currently, selpercatinib and pralsetinib are the two FDA-approved RET-inhibitors that selectively target the RET protein.寻找适合短线交易者的日内行情机会。 While these treatments show great benefit in most patients, within 1-3 years many RET-positive lung cancer patients become resistant to the therapies and their cancer progresses again. Finding new therapies that prevent resistance and are effective long-term is critical.

Learn more about RET-positive NSCLC

I have witnessed first hand how the Happy Lungs Project has transformed the journey of my beloved niece who has lung cancer. I am so grateful for their collaborative approach in bringing together top experts, advocating and funding critical research and connecting her with compassionate doctors who truly understand her needs.

Faanya RoseFamily member

The Happy Lungs Project has transformed my journey with lung cancer. They helped me to understand the science and the best next steps during the unimaginable, proving that I am never alone in this fight. I am grateful for their support and their unrelenting focus on research.

AnonymousPatient

The HLP is a lifeline for our RET-positive community. Beyond groundbreaking research and specialized physician access, they bring something essential: hope. And hope is the foundation needed to face and fight this disease.

Dolores ParkerSupporter

Watching my husband live with stage 4 lung cancer feels like living in everlasting darkness. But then there’s Happy Lungs. It’s more than an organization; it’s hope and a glimmer of light piercing through the darkness, a family I never knew I needed.

AnonymousCaregiver

Proudly Collaborating With These Organizations 日内交易机会

Lilly pharmaceutical clinical trial
MD Anderson lung cancer center
Lungeveity
RET positive group
ret renegades Lung Cancer
cancer prevention research institute of Texas
UT southwestern medical non-small cell lung cancer research
massachusetts general hospital RET lung cancer partner
memorial sloan kettering non-small cell lung cancer
GO2 RET lung cancer education
biomarker collaborative NSCLC ret inhibitor research
23andMe lung cancer registry